CytomX Therapeutics, Inc. (CTMX) Stock Grade

About CytomX Therapeutics, Inc.'s fundamentals

CytomX Therapeutics is a mid-sized biotechnology company with a market capitalization of $587.6 million that is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -22.8%. The company experienced significant revenue contraction, declining 44.8% year-over-year, indicating a substantial drop in sales performance. With no dividend yield and the absence of positive earnings metrics, the company is in a pre-profitability or transitional phase typical of development-stage biotech firms focused on pipeline advancement rather than current financial returns.